This article was originally published here
Cardiovasc Diabetol. 2021, May 7; 20 (1): 99. doi: 10.1186 / s12933-021-01286-7.
ABSTRACT
RATIONAL: Approximately 50% of patients with...
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...